MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/jtd-2026-1715

Медицинская библиотека · Journal of thoracic disease · 2026

Real-world survival outcomes following multimodal surgical treatment for stage IIIA non-small cell lung cancer.

Carroway William P, Liang Elaine, Jiang Sheng-Fang, Jarrin Lopez Alberto, Williams Kenneth, Velotta Jeffrey B

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Stage IIIA non-small cell lung cancer (NSCLC) is a heterogeneous disease, and the role of surgery within multimodality treatment remains controversial. With the emergence of immunotherapy, there is a need to re-evaluate surgical outcomes in real-world populations. This study compares overall survival (OS) between surgical and non-surgical approaches for stage IIIA NSCLC from a multicenter cohort.

METHODS

We conducted a retrospective cohort study of 598 stage IIIA NSCLC patients diagnosed between January 1, 2010, and June 30, 2021, across 21 Kaiser Permanente Northern California (KPNC) hospitals. Patients were categorized into surgical and non-surgical groups; the surgical group was further divided into surgery alone, surgery first (adjuvant therapy), and surgery later (neoadjuvant or perioperative therapy).

RESULTS

The surgical group had higher 5-year OS (52.6% vs. 30.8%, P<0.001) and longer median survival (5.77 vs. 2.17 years). All surgical subgroups were independently associated with reduced mortality after adjusting for age, sex, body mass index (BMI), smoking status, Charlson Comorbidity Score (CCS), and race: surgery later [adjusted hazard ratio (AHR) =0.50; 95% confidence interval (CI): 0.34-0.74], surgery alone (AHR =0.58; 95% CI: 0.39-0.89), and surgery first (AHR =0.48; 95% CI: 0.37-0.62). Age >80 years (AHR =1.65; 95% CI: 1.07-2.55; P=0.02) and male sex (AHR =1.64; 95% CI: 1.30-2.06; P<0.001) were independently associated with increased mortality.

CONCLUSIONS

Surgery, when integrated into multimodal treatment, is associated with significantly improved survival in stage IIIA NSCLC. These findings support continued consideration of surgery in appropriately selected patients and highlight the need for prospective studies to clarify its role in NSCLC management.

Для цитирования: Carroway William P, Liang Elaine, Jiang Sheng-Fang, Jarrin Lopez Alberto, Williams Kenneth, Velotta Jeffrey B. Real-world survival outcomes following multimodal surgical treatment for stage IIIA non-small cell lung cancer.. Journal of thoracic disease. 2026. DOI: 10.21037/jtd-2026-1715.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.